Documented Case Study #2 of Missed Cancer by Radiology

Study Background - Patient Clinical History:

We had an 80-year-old male patient, remarkably healthy and active, come to our clinic with concerns regarding his steadily rising PSA levels, now measured at 6.9 ng/mL. Notably, he had a negative prostate biopsy approximately five years ago. A subsequent digital rectal exam (DRE) uncovered an area of mild induration in the right mid-gland.

On January 19, 2024, a multi-parametric MRI (mpMRI) of the prostate was performed. The radiologist’s initial interpretation reported no measurable suspicious abnormalities, assigning a PI-RADS score of 1. This would typically suggest a very low likelihood of clinically significant prostate cancer.

However, leveraging the capabilities of Bot Image’s ProstatID for an AI-assisted interpretation of the same MRI study presented us with a starkly contrasting view. The AI identified a PI-RADS 5 region, indicating a significant lesion involving much of the central gland bilaterally, and a PI-RADS 2 lesion in the right peripheral zone.

Informed by the AI’s findings, we proceeded with an MRI-informed cognitive fusion transperineal prostate biopsy on March 7, 2024. The biopsy pathology confirmed the presence of adenocarcinoma, Grade Group 2.


This case profoundly demonstrates the utility of AI-assisted prostate mpMRI interpretation. Without this technology, it is doubtful a biopsy would have been pursued due to the patient’s advanced age and the seemingly negative MRI findings. ProstatID has shown to be an invaluable tool in guiding clinical decisions and impacting patient management positively.

Enclosed are redacted documents detailing this case for your review. My preliminary experiences with Bot Image ProstatID suggest it is swiftly becoming essential in the standard of care for prostate disease detection, diagnosis, and management.

I am excited about the role of AI in healthcare and the specific benefits ProstatID is bringing to patients. I look forward to your thoughts on integrating this evolving technology on a broader scale to enhance patient outcomes.

Warm regards,

Dr. D. Russell Locke, M.D.